Ding Ye, Zhang Miao, Zhang Wencheng, Lu Qiulun, Cai Zhejun, Song Ping, Okon Imoh Sunday, Xiao Lei, Zou Ming-Hui
From the Center for Molecular and Translational Medicine, Georgia State University, Atlanta (Y.D., Q.L., Z.C., P.S., I.S.O., L.X., M.-H.Z.); Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City (M.Z.); and The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital of Shandong University, Jinan, China (W.Z.).
Circ Res. 2016 Sep 2;119(6):718-30. doi: 10.1161/CIRCRESAHA.116.308689. Epub 2016 Jul 20.
AMP-activated protein kinase (AMPK) has been reported to play a protective role in atherosclerosis. However, whether AMPKα2 controls atherosclerotic plaque stability remains unknown.
The aim of this study was to evaluate the impact of AMPKα2 deletion on atherosclerotic plaque stability in advanced atherosclerosis at the brachiocephalic arteries and to elucidate the underlying mechanisms.
Features of atherosclerotic plaque stability and the markers for contractile or synthetic vascular smooth muscle cell (VSMC) phenotypes were monitored in the brachiocephalic arteries from Apoe(-/-)AMPKα2(-/-) mice or VSMC-specific AMPKα2(-/-) mice in an Apoe(-/-) background (Apoe(-/-)AMPKα2(sm-/-)) fed Western diet for 10 weeks. We identified that Apoe(-/-)AMPKα2(-/-) mice and Apoe(-/-)AMPKα2(sm-/-) mice exhibited similar unstable plaque features, aggravated VSMC phenotypic switching, and significant upregulation of Kruppel-like factor 4 (KLF4) in the plaques located in the brachiocephalic arteries compared with those found in Apoe(-/-) and Apoe(-/-)AMPKα2(sm+/+) control mice. Pravastatin, an AMPK activator, suppressed VSMC phenotypic switching and alleviated features of atherosclerotic plaque instability in Apoe(-/-)AMPKα2(sm+/+) mice, but not in Apoe(-/-)AMPKα2(sm-/-) mice. VSMC isolated from AMPKα2(-/-) mice displayed a significant reduction of contractile proteins(smooth muscle actin-α, calponin, and SM-MHC [smooth muscle-mysion heavy chain]) in parallel with increased detection of synthetic proteins (vimentin and osteopontin) and KLF4, as observed in vivo. KLF4-specific siRNA abolished AMPKα2 deletion-induced VSMC phenotypic switching. Furthermore, pharmacological or genetic inhibition of nuclear factor-κB significantly decreased KLF4 upregulation in VSMC from AMPKα2(-/-) mice. Finally, we found that AMPKα2 deletion markedly promoted the binding of nuclear factor-κBp65 to KLF4 promoter.
This study demonstrated that AMPKα2 deletion induces VSMC phenotypic switching and promotes features of atherosclerotic plaque instability in nuclear factor-κB-KLF4-dependent manner.
据报道,AMP激活的蛋白激酶(AMPK)在动脉粥样硬化中发挥保护作用。然而,AMPKα2是否控制动脉粥样硬化斑块稳定性仍不清楚。
本研究旨在评估AMPKα2缺失对头臂动脉晚期动脉粥样硬化中动脉粥样硬化斑块稳定性的影响,并阐明其潜在机制。
在喂食西方饮食10周的Apoe(-/-)AMPKα2(-/-)小鼠或Apoe(-/-)背景下的血管平滑肌细胞特异性AMPKα2(-/-)小鼠(Apoe(-/-)AMPKα2(sm-/-))的头臂动脉中,监测动脉粥样硬化斑块稳定性特征以及收缩型或合成型血管平滑肌细胞(VSMC)表型的标志物。我们发现,与Apoe(-/-)和Apoe(-/-)AMPKα2(sm+/+)对照小鼠相比,Apoe(-/-)AMPKα2(-/-)小鼠和Apoe(-/-)AMPKα2(sm-/-)小鼠在头臂动脉中的斑块表现出相似的不稳定斑块特征、加重的VSMC表型转换以及Kruppel样因子4(KLF4)的显著上调。AMPK激活剂普伐他汀抑制了Apoe(-/-)AMPKα2(sm+/+)小鼠的VSMC表型转换并减轻了动脉粥样硬化斑块不稳定的特征,但对Apoe(-/-)AMPKα2(sm-/-)小鼠无效。与体内观察结果一致,从AMPKα2(-/-)小鼠分离的VSMC显示收缩蛋白(平滑肌肌动蛋白-α、钙调蛋白和SM-MHC[平滑肌肌球蛋白重链])显著减少,同时合成蛋白(波形蛋白和骨桥蛋白)和KLF4的检测增加。KLF4特异性小干扰RNA消除了AMPKα2缺失诱导的VSMC表型转换。此外,核因子-κB的药理学或遗传学抑制显著降低了AMPKα2(-/-)小鼠VSMC中KLF4的上调。最后,我们发现AMPKα2缺失显著促进了核因子-κBp65与KLF4启动子的结合。
本研究表明,AMPKα2缺失以核因子-κB-KLF4依赖的方式诱导VSMC表型转换并促进动脉粥样硬化斑块不稳定的特征。